chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Neck and axillary lymph node swelling. Painful for 1-2 weeks.
There were no adverse events associated with the administration of this vaccine, however, it was discovered that the patient was16 years old and Moderna is only indicated for 18 and up. We have been continuously monitoring the patient and have seen no adverse events since.
?After 1st day and a half was fine; then went down hill from there could not think clear.?  Sunday felt like I had fever and did not take temperature could not get out of bed.  On Monday went to work out ?Tired? and ?Chest tightness? and called husband.  ?Hx of heart murmur?  Called cardiologist yesterday;  Dr.,  appointment scheduled tomorrow 05.19.21. She continues with headache, tired and nose running
Patient of 10 years of age was given the 12+ Pfizer Covid vaccine. Licensed Vocational Nurse administered vaccine on the left arm. Realized incorrect dosage when placing the vaccine. Failed to perform 3 safety checks per company policy. Patient did not experience any adverse affects. Patient was monitored for 15 min.
This spontaneous report as received from a healthcare worker refers to a 15 year old female patient. At the time of reporting the patient was not pregnant. No other pertinent medical history was reported. On 13-JUN-2012 the patient was vaccinated with GARDASIL (dose 1, 0.5 ml, intramuscular, anatomical location and lot number was not reported). The reporter stated that there was no information available as to whether there were any adverse effects after the first dose was administered. On 13-MAY-2014 the patient was vaccinated with GARDASIL (dose 2, 0.5 ml, intramuscular, anatomical location and lot number was not reported). No concomitant medications were reported. On 16-MAY-2014 the patient had developed hives all over her body after her injection, but more concentrated on her legs. None lab diagnostics studies were performed. It was unclear if the patient received any treatment. The outcome of event was reported as resolved (on 19-MAY-2014). The relatedness between event and GARDASIL. Additional information is not expected.
101.7 temperature; Swelling of face; joint pain; muscle pain; headache; chills; tired; lump in injection spot; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO150) via an unspecified route of administration in the right arm on 13Apr2021 at 21:30 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included ulcerative colitis, blood pressure high and allergies. The patient received unspecified medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 the patient experienced 101.7 temperature, swelling of face, joint pain, muscle pain, headache, chills, tired and lump in injection spot. The patient called doctor and was waiting to hear from them. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. On an unknown date, the patient underwent body temperature and the result was 101.7 (units unspecified). Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event 101.7 temperature. swelling of face, joint pain, muscle pain, headache, chills, tired, lump in injection spot was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
3/2 early afternoon after vaccine #2 experienced weakness, chills, and body temperature fluctuations for about 1 1/2 hours . Resolved af 1 1/2 hours.
1st dose on 14Oct2021, 2nd dose not received; This case was reported by a consumer via call center representative and described the occurrence of incomplete course of vaccination in a 65-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 14th October 2021).   On an unknown date, the patient did not receive the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.   Additional Information: GSK Receipt Date: 09-SEP-2022 Reporter's comment: The case was self reported by the patient. The patient mentioned he forgot to get his second dose of Shingrix. The patient had nothing else to report. The reporter or patient did not want to be contacted. The reporter did not consent to follow up. The details were provided for 1st dose as 2nd dose was not administered. Additional Supportive Information: Till the time of reporting, the patient did not receive 2nd dose of Shingrix, which led to incomplete course of vaccination.
devel fever 10 p/inject temp up to 102;  swelling of lt ankle & lt thigh;
The day following vaccine, pt started to have nerve pain from the site of admin to left hand, then radiate to right clavicle. On 3/9/14 (2 days after) he started to experience nerve pain in the mouth and swollen lymph node behind left ear. He took TYLENOL and will get x-ray from his dentist.
Information has been received from a nurse concerning a 12 month old patient who on 29-MAY-2008 was vaccinated subcutaneously with a 0.65 ml dose of ZOSTAVAX (Merck) instead of VARIVAX (Merck). There was no product confusion. The incident was due to human error. The patient has not experienced any known symptoms. NO product quality complaint was involved. Additional information has been requested.
No additional AE reported; improperly stored PROQUAD was administered to a patient on 23Aug2022.; This spontaneous report was received from a medical assistant concerning a patient of unknown age and gender.   The patient's medical history, concurrent conditions and concomitant therapies were not reported.   On 23-AUG-2022, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (recombinant Human albumin) (PROQUAD), lot #W017567, expiration date: 29-NOV-2023, administered as prophylaxis (strength and route of administration was not provided), after a temperature excursion of 1 hour at a temperature of  -10 Celsius degrees (C) up to 8 C (-9.6C) degrees (product storage error). No previous temperature excursions and no additional adverse events were reported
PATIENT CAME TO THE PHARMACY ON 9-13-2019.HER UPER LEFT ARM WAS BLACK AND BLUE . HER ARM WAS SORE. I REFERED HER TO DR.
Breakthrough case admission after three doses; patient expired Moderna, 2/10/21, Lot #007M20A,  Moderna 3/10/21, Lot #030A21A,   Moderna 11/18/21, Lot #039F21A
Cough started 12-8-09 chest x-ray on AMOXICILLIN x 10 days H1N1 on 12-18-09 cough and SOB started 12-19-09 tired intermittent fever/chills mild throat tenderness sinus drainage Eosinophils elevated could be isolated to H1N1. Prednisone taken and COMBIVENT
Pt c/o pain at injection site beginning 4/13/09 in the evening. States she noticed inflammation, redness, and warmth at injection site on 4/15/09. Relief of symptoms on 4/16/09. To apply warm compress to site.
not in the mood, I'm in pain right now; wouldn't have called if it wasn't so bad; pain is sore; it was horrible last night; fever; injection site pain; little bit of chills; feeling specific pectoral muscle pain; This spontaneous case was reported by a consumer and describes the occurrence of FEELING ABNORMAL (not in the mood, I'm in pain right now), FEELING ABNORMAL (wouldn't have called if it wasn't so bad), PAIN (pain is sore), PAIN (it was horrible last night) and PYREXIA (fever) in a 59-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.   On 19-Sep-2021 at 4:00 PM, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced FEELING ABNORMAL (not in the mood, I'm in pain right now), FEELING ABNORMAL (wouldn't have called if it wasn't so bad), PAIN (pain is sore), PAIN (it was horrible last night), PYREXIA (fever), VACCINATION SITE PAIN (injection site pain), CHILLS (little bit of chills) and MYALGIA (feeling specific pectoral muscle pain). The patient was treated with ACETYLSALICYLIC ACID (ASPIRIN (E.C.)) for Adverse event, at an unspecified dose and frequency. At the time of the report, FEELING ABNORMAL (not in the mood, I'm in pain right now), FEELING ABNORMAL (wouldn't have called if it wasn't so bad), PAIN (pain is sore), PAIN (it was horrible last night), PYREXIA (fever), VACCINATION SITE PAIN (injection site pain), CHILLS (little bit of chills) and MYALGIA (feeling specific pectoral muscle pain) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: high (High) a degree and a half of temperature.         Concomitant medications was not provided by the reporter Treatment  Ice  The patient was rude and said it was not in the mood, I'm in pain right now, pain is sore, in the past a little bit of chills, fever but now I'm feeling specific pectoral muscle pain. The patient received the doses in the left arm. On Sunday it felt injection site pain and on Monday started to feel the pectoral. The patient said it was horrible last night it was terrible and that wouldn't have called if it wasn't so bad.
Severe vertigo that lasted 24 hrs. Threw up every time tried to sit up.  Been dizzy ever since, have a hissing sound nonstop in my head and a low-grade headache non-stop.  Receive a second shot on 2/25/21 and three days later had another severe vertigo episode. Lasted about 6-8 hrs. Still have low-grade headache and dizziness. to this day.
This case was considered medically important. Information regarding PREVNAR was received from a consumer regarding a 28 day old male patient who was administered the first dose of PREVNAR at 14 days old and then at 28 days old experienced a body temperature of 104. At 14 days of age, the patient received the first dose on an unspecified date. The patient was administered the first dose of PREVNAR at 14 days old. When he was 28 days old, the patient was admitted to the hospital for a body temperature of 104. The fever resolved within a few hours, however remained hospitalized for 3 days because the mother refused a spinal tap. See related case(s): US WYE H17382110 (Adverse event, expedited).
Patient was waiting the 30 minutes after the vaccine was given, she started getting tightening of throat, and tachycardia.  She was taken to the Emergency room at the Hospital where she was given 50 mg of Benedryl.
Pt received third pfizer vaccine per the primary series but because new regulations came out stating to hold off on third vaccine until we as a company receive the booster for 6 month to 4 years this wasn't the recommended vaccine for patient per new regulations
Moderate to severe inflammation, erythema, and pain L upper arm which spread to the lower R arm below the elbow.
Patient complained of left arm pain and body aches as well as fever post vaccination. Patient took ADVIL the night of and spoke to a member of our medical team the next day. Recommended to patient: Start cool compresses or frozen pack of peas. NSAIDs for pain/irritation, low grade fever. Monitor malaise closely, if Sx not resolving in next 24 hours, please call VMT/consider OV. Red flags advised, callback if no improvement within 24H, sooner if worsening.
Initial information received from nurse on 15-Oct-2013: Patient received FLUZONE ID (Lot unknown) on 09-Oct-2013. Patient reported that her left shoulder became red, swollen and tender to touch, shortly after vaccination. 7 days after vaccination, area is still sore and tender. No further relevant information reported.
racing heart beat of 100 per minute.; experiencing a fever of 101; This case was reported by a consumer and described the occurrence of heart rate increased in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On 3rd January 2021, the patient received the 2nd dose of Shingrix. On 4th January 2021, 1 days after receiving Shingrix, the patient experienced heart rate increased and fever. On an unknown date, the outcome of the heart rate increased and fever were not recovered/not resolved.   It was unknown if the reporter considered the heart rate increased and fever to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not provided. The reporter was patient's wife. The patient received 2nd dose of Shingrix, and experienced increased heart rate of 100 beats per minute and  fever of about 101 degree Celsius. The reporter did not consent to follow up.
Systemic: Dizziness / Lightheadness-Medium, Systemic: Weakness-Medium, Additional Details: PT PALE AND WEAK
Patient reported tinnitus that started shortly after first dose of vaccine, exact date unknown.  Received second vaccine on 2/25/21  lot EN6200.  Patient advised facility of possible reaction May 2021 as tinnitus had continued.  Advised to discuss with primary care physician.  Patient commented that she had.
day p/vax 11SEp93 pt had t100.3 R; diarrhea 12SEP; severe vomiting 13SEP; lethargic; intermittant fever till 13SEP; TOlerating clear liqs 14SEP93; no rx;
Thursday 3:15 vaccination  1. Felt really heavy arm almost right away. 2. While working my 3-11 shift, I felt really getting tired ,sore and pain everywhere. 3. Getting uneasy feeling but still had to work because we are short staffed. 4. By 9pm starting to have severe headache and pain in my  lower right quadrant. 5. By 10pm headache is getting worse and starting to get nauseous.  Made it to my whole 8hr shift,thankfully I have a very good coworker.  Saturday is the worst day of my life. I felt like I'm dying with the severe headache,stomach pain ,lower right quadrant pain unbearable. Dizziness and nauseous . All of my reactions are so severe I thought I need to go to hospital.
I21.4 ACUTE NON ST ELEVATION MI 5/18/2021 CHF (CONGESTIVE HEART FAILURE), UNSPECIFIED I95.9 HYPOTENSION 9/20/2021 CHF (CONGESTIVE HEART FAILURE), UNSPECIFIED I21.4 ACUTE NON ST ELEVATION MI 5/18/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA I95.9 HYPOTENSION 9/20/2021 CAD (CORONARY ARTERY DISEASE) WO ANGINA
Initial imbalance, "floppiness" Persistent fatigue 1 week later, onset of cognitive symptoms and insomnia -difficult time finding things at home, even when right in front of her (visuospatial inattention), misplacing things - missing words and wrong tense when writing, paraphasias, misspellings -trouble following stories communicated to her verbally -trouble understanding sentences she had typed -difficulty expressing her reasoning in document writing while at work -poor concentration Also onset of mild anxiety and fluctuating sadness Intermittent early satiety and lack of appetite  Treatment:  Melatonin 6mg 3-5hrs before sleep CBD oil 50mg nightly (she had started this before presenting to me on 1/30/21) I started her on gabapentin 300mg, she had some relief of sleep onset insomnia, still had middle-of-night awakenings without return to sleep, so added zaleplon PRN for rescue. Zaleplon insufficient duration so switched to Zolpidem PRN. She has not required more than a few doses of zolpidem but now we have uptitrated her to gabapentin 600mg nightly. She feels significant improvement in her sleep and work product, but continues to have intermittent cognitive errors and some decrease in work performance, that remain concerning to her.
Patient did not experince any symptoms; administered a dose of improperly stored VARIVAX; administration to be intramuscular rather than subcutaeous; This spontaneous report was received from a nurse, referring to a patient of unknown age and gender. Information regarding the patient's pertinent medical history, concurrent condition and drug allergies/reactions were not reported.    On 17-JUL-2019, the patient was vaccinated with an improperly stored dose (product storage error) of varicella virus vaccine live (oka/merck) (VARIVAX) (strength, dose, schedule were not provided) (lot # R002057, expiry date: 22-JAN-2022) via intramuscular route (incorrect route of product administration) for prophylaxis. The vaccine was reconstituted with properly stored sterile diluent (reported as "did not experience a temperature excursion"). The vaccine underwent a temperature excursion of 15 degree Fahrenheit to 46 degree Fahrenheit (18.3 Fahrenheit) for a duration of 1 hour 15 minutes. The vaccine previously underwent a temperature excursion of 15 degree Fahrenheit to 46 degree Fahrenheit (34.5 Fahrenheit) for a duration of 2 hours 33 minutes. There was involvement of data logger. The nurse reported that, the patient did not experience any symptoms (no adverse event). There was no associated product quality complaint.
pt admitted to hosp  12/24/21 with SOB; had a recent dx on 12/23/21 with a positive COVID test; given O2 supplementation; condition worsened and he was transferred to CCU; intubated and sedated; given dexamethasone, remdesivir, baricitinib, ABX; renal function worsened; pt was made comfort care; palliatively extubated and passed away in the hosp
Patient received the flu shot at an off site flu clinic at the Court House. RN left after all employees received vaccine. The RN was called about 30 minutes later and informed the patient had difficulty breathing and was itching, they transported her to the ER. RN called the employee who drove the patient to the ER and said she was given meds IV ans sent hone about 1.5 hour later. RN called to follow up with the patient on 10/12/18, patient was fine and had returned to work.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. The patient's healthcare provider recommended and/or prescribed ZOSTAVAX to the patient for its intended purpose of permanent prevention and protection against shingles and zoster-related conditions. On or about 2013, a healthcare provider administered the ZOSTAVAX to the patient (lot number, dosage and route of administration not provided). On or about 2016, the patient was treated by a healthcare provider for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX vaccine, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death; aggravation of preexisting conditions and activation of latent conditions (unspecified); lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
This case was reported by a nurse via call center representative and described the occurrence of chills in a 55-year-old female patient who received SHINGRIX (batch number 5NY3B, expiry date 13th July 2020). On 21st May 2018, the patient received the 1st dose of SHINGRIX. On 21st May 2018, less than a day after receiving SHINGRIX, the patient experienced chills. On 22nd May 2018, the patient experienced fever, headache and influenza-like symptoms. On 24th May 2018, the outcome of the fever was recovered/resolved. On an unknown date, the outcome of the chills and influenza-like symptoms were unknown and the outcome of the headache was not recovered/not resolved. It was unknown if the reporter considered the chills, fever, headache and influenza-like symptoms to be related to SHINGRIX. Additional details were provided as follows: In the evening of the vaccination day, the patient experienced chills and shivering. One day after vaccination, the patient experienced headache, felt like a low grade fever, flu-like symptoms, and did not go to work. On 23rd May 2018, the patient felt better but had a 101 F temperature at 12 noon and slept all day. By 24th May 2018 morning the patient still had the headache and no fever. No additional information was provided.
Inappropriate Schedule of Vaccine; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 71-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix  (1st dose received in October 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were received as follows: The age at vaccination was not applicable for this report. The reporter asked how proceed with Shingrix 2nd dose, which led to incomplete course of vaccination. The reporter consented to follow up.
No adverse event problem occurred. Nurse administered pediatric dose to adult patient. Explained to patient, consulted with immunization coordinator & nurse manager. District permission received to immunize patient with adult dose. Nurse administered adult dose to patient with no symptoms of adverse event.
Severe chills, weakness, dizziness, inability to hold self up, extreme lethargy, loss of appetite. Have taken temp and BP and both are normal. Pushing fluids, and keeping warm.
One hour after - shooting pain down left arm for several hours, took APAP for pain slight soreness at injection site the next day.
RED FLUSHED, MEDICINE TASTE, DAY 4 - LUNGS CLOSED. HAD TO DO INHALER, DIZZINESS WHICH HAS NOT GONE AWAY, BP AND HEARTRATE WENT HIGH, TOOK BP PILL FOR 5 DAYS TO GET IT LOWERED, HEARTRATE IS LOWERED AS WELL-ON BETA BLOCKERS
rash at the injection site; rash has since spread throughout her body; This case was reported by a other health professional via call center representative and described the occurrence of injection site rash in a 64-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix (intramuscular). On an unknown date, 1 day after receiving Shingrix, the patient experienced injection site rash and rash. The patient was treated with prednisone. On an unknown date, the outcome of the injection site rash and rash were not recovered/not resolved.   It was unknown if the reporter considered the injection site rash and rash to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient developed a rash at the injection site the day after getting Shingrix. The rash has since spread throughout her body and was still present. The patient has been treated with prednisone.
Fever of 103F for 2 days, 8 days, post vax. Rash developed 10 days, post vax.
pt recvd vax 12OCT95 & 7AM 13OCT had probable sz w/fever; generalized w/arm shaking, staring, unresponsive;drowsy about 45mins;
The next day, the injection site was hot to the touch, swollen, itchy, and hard. It went away after another day or two, but now it is back (11 days later). It is not as swollen but it is itchy, warm, and hard.